We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic Drugmakers Denied Rehearing on Validity of Vimpat Patent
Generic Drugmakers Denied Rehearing on Validity of Vimpat Patent
The U.S. Court of Appeals for the Federal Circuit Friday denied a request by generic drugmakers for a rehearing to challenge an epilepsy drug patent’s validity.